Alaunos Therapeutics, Inc. - TCRT STOCK NEWS

Alaunos Therapeutics (TCRT) announces key milestones for 2023, including the addition of two new TCRs, doubling the addressable market for its TCR-T library. The company aims to enhance patient enrollment in its Phase 1/2 trial focusing on solid tumors. Manufacturing processes are being optimized for scalability, with a shift to cryopreserved products expected to reduce processing time. The mbIL-15 program is also advancing towards an IND filing in the latter half of 2023. As of Q4 2022, Alaunos reported cash and equivalents of approximately $39.1 million, projected to fund operations into Q4 2023.

Alaunos Therapeutics, Inc. (TCRT) announced a public offering of approximately 24.23 million shares at a gross proceeds of $15.7 million. The offering is set to close around December 1, 2022, subject to standard conditions. The funds will be used for the development of its product candidates and general corporate purposes. The underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase additional shares. A registration statement related to the offering has been filed with the SEC.

Alaunos Therapeutics, Inc. (TCRT) has announced an underwritten public offering of its common stock, with a 30-day option for the underwriter to purchase an additional 15% of shares. The proceeds will be used to support product development, working capital, and general corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager. The offering is contingent upon market conditions and may not proceed as planned. The registration statement for this offering was declared effective on September 7, 2022, with relevant documents available through the SEC.

Alaunos Therapeutics (TCRT) reports promising early data from its TCR-T Library Phase 1/2 trial, showcasing the first objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CICON conference. The company aims to treat more patients while expanding manufacturing capabilities to produce two products simultaneously. Financially, collaboration revenue surged 631% to $2.9 million, while net loss decreased to $8.9 million, improving cash burn by 36%. An IND amendment is expected to enhance speed and flexibility in manufacturing.

Alaunos Therapeutics (TCRT) will announce its financial results for Q3 2022 on November 14, 2022, prior to U.S. market opening. Following this, a conference call will be held at 8:30 a.m. ET to discuss the results and provide a corporate update. The company specializes in oncology-focused cell therapies, utilizing its proprietary Sleeping Beauty gene transfer technology to develop T-cell receptor therapies targeting oncogenic gene mutations like KRAS, TP53, and EGFR.

Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has announced promising data from its human neoantigen T-cell receptor platform (hunTR) at the Society for Immunotherapy of Cancer's annual meeting. The proprietary hunTR platform enables rapid identification of neoantigen-reactive TCRs, enhancing Alaunos' TCR library. The study evaluated ~525,000 TCR+HLA+neoantigen combinations in patients with various cancers, with a median hit rate of 13% per patient. The company plans to expand the application of hunTR for additional mutations, aiming to advance personalized TCR-T therapies.

Alaunos Therapeutics has announced promising early clinical data from its TCR-T Library Phase 1/2 trial for treating solid tumors. The first patient experienced a confirmed partial response with a 51.2% tumor regression at three months post-infusion. The Sleeping Beauty TCR-T cell therapy demonstrated a manageable safety profile, with no dose-limiting toxicities observed. The data will be presented at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference on September 30, 2022. This therapy targets shared tumor-specific hotspot mutations, offering hope for patients with significant unmet medical needs.

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, announced participation in several investor conferences. Key events include:

• Wells Fargo Healthcare Conference on September 8, 2022, in Boston, MA (1x1 Meetings)
• Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, in New York, NY (1x1 Meetings)
• Cantor Oncology Conference on September 28, 2022, in New York, NY (Panel Presentation and 1x1 Meetings)

Alaunos Therapeutics has reported significant early findings from its TCR-T Library Phase 1/2 trial, marking a first objective clinical response in solid tumors via non-viral TCR-T cell therapy. The initial patient, diagnosed with non-small cell lung cancer and a KRAS mutation, exhibited a confirmed objective partial response. A second patient has completed the 28-day safety window. The results will be further detailed at the CRI-ENCI-AACR CICON conference on September 30, 2022, highlighting the potential of non-viral TCR-T therapies in treating solid tumors.